Abbott India Ltd is a development,
manufacture and marketing of
pharmaceutical, diagnostic, nutritional &
hospital products in India.
Abbott India has received CE Mark for
XIENCE (Xpedition™ Everolimus Eluting
Coronary Stent System) & the company is
launching the product immediately in CE
Mark countries.
Abbott India has signed an agreement to
collaborate with Astellas Pharma Global
Development in a Phase 3 clinical trial for
TransVax™.
Abbott's Omnilink Elite® Vascular
Balloon-Expandable Stent System
receives FDA approval for Treatment of
Iliac Artery Disease.
Abbott India receives FDA Approval for
Healon EndoCoat Protective Gel for
Cataract Surgery.
During the quarter, the robust growth of
Net Profit is increased by 72.63% to Rs.
295.20 million.
Abbott India has declared a quarterly
dividend of 51 cents per share. The cash
dividend is payable on Nov. 15, 2012, to
shareholders.
Net Sales and PAT of the company are
expected to grow at a CAGR of 26% and
42% over 2010 to 2013E respectively.
Latest Updates
• Abbott India Limited has declared a quarterly dividend of 51 cents per share. The cash dividend is payable
Nov. 15, 2012, to shareholders of record at the close of business on Oct. 15, 2012. Abbott has increased its
dividend payout for 40 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which
tracks companies that have annually increased their dividend for 25 consecutive years.
• Abbott India Ltd as a member of the Dow Jones Sustainability World Index, the company’s rank among the
top 300 of the 2,500 largest companies worldwide in corporate sustainability by applying core capabilities
and expertise in new & innovative ways. The prestigious Dow Jones Sustainability Indexes (DJSI) recognizes
the leading companies in each industry sector for responsible economic, environmental and social
performance.
• Abbott India has signed an agreement to collaborate with Astellas Pharma Global Development in a Phase 3
clinical trial for ASP0113 (TransVax™), an investigational vaccine licensed from Vical Incorporated for
preventing cytomegalovirus (CMV) reactivation in transplant patients.
• Abbott has CE Marking (Conformite Europeenne) for a testosterone assay with improved sensitivity and
clinical utility. With a simple blood test, the ARCHITECT 2nd Generation Testosterone Assay can accurately
measure the wide range of testosterone levels seen in a number of different patient populations and clinical
settings.
• Abbott India (XIENCE Xpedition™ Everolimus Eluting Coronary Stent System) has received CE Mark in
Europe for the treatment of coronary artery disease. The company is launching the product immediately in
CE Mark countries. XIENCE Xpedition features a new stent delivery system designed to optimize acute
performance, particularly in challenging coronary anatomies. XIENCE Xpedition is available with a broad
range of indications, including use with a minimum duration of three months of dual anti-platelet therapy
(DAPT).
• Abbott's Omnilink Elite® Vascular Balloon-Expandable Stent System Receives FDA Approval for Treatment
of Iliac Artery Disease.
• Abbott India receives FDA Approval for Healon EndoCoat Protective Gel for Cataract Surgery.
No comments:
Post a Comment